In vitro permeation and in vivo anti-inflammatory and analgesic properties of nanoscaled emulsions containing ibuprofen for topical delivery

International Journal of Nanomedicine

Volumn 6, Issue , 2011, Pages 387-396

  Abdullah, Ghassan Z ^a   Abdulkarim, Muthanna F ^a   Salman, Ibrahim M ^a   Ameer, Omar Z ^a   Yam, Mun F ^a,b   Mutee, Ahmed F ^a   Chitneni, Mallikarjun ^c   Mahdi, Elrashid S ^a   Basri, Mahiran ^b   Sattar, Munavvar A ^a   Noor, Azmin M ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Anti inflammatory effects; In vivo analgesic

Indexed keywords

CARBOMER; IBUPROFEN; LIMONENE; MENTHOL; TRIETHANOLAMINE; ACRYLIC ACID RESIN; CARBOPOL 940; ETHANOLAMINE DERIVATIVE; NANOMATERIAL; NONSTEROID ANTIINFLAMMATORY AGENT; PALM OIL; POLYSORBATE; SURFACTANT; VEGETABLE OIL;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARRAGEENAN-INDUCED PAW EDEMA; CONTROLLED STUDY; DIFFUSION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MALE; NONHUMAN; RAT; STEADY STATE; THERMODYNAMICS; TOPICAL DRUG DELIVERY SYSTEM; ANIMAL; CHEMISTRY; DRUG EFFECT; EMULSION; EVALUATION; METABOLISM; NANOMEDICINE; PAIN THRESHOLD; PERMEABILITY; SKIN; TOPICAL DRUG ADMINISTRATION; WISTAR KYOTO RAT;

ACRYLIC RESINS; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EMULSIONS; ETHANOLAMINES; IBUPROFEN; NANOMEDICINE; NANOSTRUCTURES; PAIN THRESHOLD; PERMEABILITY; PLANT OILS; POLYSORBATES; RATS; RATS, INBRED WKY; SKIN; SURFACE-ACTIVE AGENTS;

EID: 80052056414     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S14667     Document Type: Article

References (52)

1. Ventre M, Mollica F, Netti PA. The effect of composition and micro-structure on the viscoelastic properties of dermis. J Biomech. 2009; 42(4):430-435.
2. Hendriks FM, Brokken D, Oomens CWJ, Bader DL, Baaijens FPT. The relative contributions of different skin layers to the mechanical behavior of human skin in vivo using suction experiments. Med Eng Phys. 2006;28(3):259-266.
3. Kaur IP, Kapila M, Agrawal R. Role of novel delivery systems in developing topical antioxidants as therapeutics to combat photoageing. Ageing Res Rev. 2007;6(4):271-288.
4. Darlenski R, Sassning S, Tsankov N, Fluhr JW. Non-invasive in vivo methods for investigation of the skin barrier physical properties. Eur J Pharm Biopharm. 2009;72(2):295-303.
5. Marjukka Suhonen TA, Bouwstra J, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release. 1999;59(2):149-161.
6. Makrantonaki E, Zouboulis CC. The skin as a mirror of the aging process in the human organism - state of the art and results of the aging research in the German National Genome Research Network 2 (NGFN-2). Exp Gerontol. 2007;42(9):879-886.
7. Nakazawa H, Yamagishi A, Imai T, et al. Study on regional differences of stratum corneum structure in human skin by electron diffraction. Chem Phys Lipids. 2008;154:S27-S27.
8. Barry BW. Novel mechanisms and devices to enable successful ŧransdermal drug delivery. Eur J Pharm Sci. 2001;14(2):101-114.
9. Al-Saidan SM. Transdermal self-permeation enhancement of ibuprofen. J Control Release. 2004;100(2):199-209.
10. Beetge E, Du Plessis J, Müller DG, Goosen C, Van Rensburg FJ. The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID’s on their transdermal absorption. Int J Pharm. 2000;193(2):261-264.
11. Godwin DA, Wiley CJ, Felton LA. Using cyclodextrin complexation to enhance secondary photoprotection of topically applied ibuprofen. Eur J Pharm Biopharm. 2006;62(1):85-93.
12. Iervolino M, Raghavan SL, Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm. 2000;198(2): 229-238.
13. Iervolino M, Cappello B, Raghavan SL, Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm. 2001;212(1):131-141.
14. Stoye I, SchrDer K, Müller-Goymann CC. Transformation of a liposomal dispersion containing ibuprofen lysinate and phospholipids into mixed micelles - physico-chemical characterization and influence on drug permeation through excised human stratum corneum. Eur J Pharm Biopharm. 1998;46(2):191-200.
15. Stott PW, Williams AC, Barry BW. Eutectic formulations of ibuprofen to enhance transdermal permeation. Eur J Pharm Sci. 1996;4(1): S147-S147.
16. Stott PW, Williams AC, Barry BW. Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. J Control Release. 1998;50(1-3):297-308.
17. Santi P, Nicoli S, Colombo G, et al. Post-iontophoresis transport of ibuprofen lysine across rabbit ear skin. Int J Pharm. 2003;266(1-2): 69-75.
18. Park E-S, Chang S-Y, Hahn M, Chi S-C. Enhancing effect of polyoxyethylene alkyl ethers on the skin permeation of ibuprofen. Int J Pharm. 2000;209(1-2):109-119.
19. Brown MB, Hanpanitcharoen M, Martin GP. An in vitro investigation into the effect of glycosaminoglycans on the skin partitioning and deposition of NSAIDs. Int J Pharm. 2001;225(1-2): 113-121.
20. Sznitowska M, Janicki S, Dabrowska EA, Gajewska M. Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions. Eur J Pharm Sci. 2002;15(5):489-495.
21. Pey CM, Maestro A, Solé I, González C, Solans C, Gutiérrez JM. Optimization of nano-emulsions prepared by low-energy emulsification methods at constant temperature using a factorial design study. Colloids Surf A Physicochem Eng Asp. 2006;288(1-3)144-150.
22. Cai H, An X, Shen W. Effects of the dispersed droplet sizes on the critical behavior of pseudobinary microemulsion. Chin Sci Bull. 2007; 52(8):1139-1141.
23. Hickey S, Hagan SA, Kudryashov E, Buckin V. Analysis of phase diagram and microstructural transitions in an ethyl oleate/water/Tween 80/Span 20 microemulsion system using high-resolution ultrasonic spectroscopy. Int J Pharm. 2010;388(1-2):213-222.
24. Kreilgaard M. Assessment of cutaneous drug delivery using microdialysis. Adv Drug Deliv Rev. 2002;54(1):S99-S121.
25. Keng PS, Basri M, Zakaria MRS, et al. Newly synthesized palm esters for cosmetics industry. Ind Crops Prod. 2009;29(1):37-44.
26. Aqil M, Ahad A, Sultana Y, Ali A. Status of terpenes as skin penetration enhancers. Drug Discov Today. 2007;12(23-24):1061-1067.
27. Dos Anjos JLV, Alonso A. Terpenes increase the partitioning and molecular dynamics of an amphipathic spin label in stratum corneum membranes. Int J Pharm. 2008;350(1-2):103-112.
28. Kang L, Yap CW, Lim PFC, et al. Formulation development of ŧransdermal dosage forms: Quantitative structure-activity relationship model for predicting activities of terpenes that enhance drug penetration through human skin. J Control Release. 2007;120(3):211-219.
29. Brain KR, Green DM, Dykes PJ, Marks R, Bola TS. The role of menthol in skin penetration from topical formulations of ibuprofen 5% in vivo. Skin Pharmacol Physiol. 2006;19(1):17-21.
30. Santoyo S, Arellano A, Ygartua P, Martn C. In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin. Pharm Acta Helv. 1996;71(2):141-146.
31. Abdullah GZ, Abdulkarim MF, Salman IM, et al. HPLC method modification and validation for quantification of ibuprofen. Int J Drug Delivery. 2010; In press.
32. Wagner H, Kostka K-H, Lehr C-M, Schaefer UF. Interrelation of permeation and penetration parameters obtained from in vitro experiments with human skin and skin equivalents. J Control Release. 2001;75(3): 283-295.
33. Larson DL, Lombardino JG. The topical anti-iflammatory effects of piroxicam in rodents. Agents Actions. 1980;10(3):246-252.
34. Sharma JN, Samud AM, Asmawi MZ. Comparison between plethys-mometer and micrometer methods to measure acute paw oedema for screening anti-inflammatory activity in mice. Inflammopharmacology. 2004;12(1):89-94.
35. Pénzes T, Blazsَ G, Aigner Z, Falkay G, Eros I. Topical absorption of piroxicam from organogels - in vitro and in vivo correlations. Int J Pharm. 2005;298(1):47-54.
36. Iwalewa EO, Iwalewa OJ, Adeboye JO. Analgesic, antipyretic, anti-inflammatory effects of methanol, chloroform and ether extracts of Vernonia cinerea less leaf. J Ethnopharmacol. 2003;86(2-3):229-234.
37. Lu G, Jun HW. Diffusion studies of methotrexate in carbopol and poloxamer gels. Int J Pharm. 1998;160(1):1-9.
38. Fresno MJC, Ramírez AD, Jiménez MM. Systematic study of the flow behaviour and mechanical properties of Carbopol® UltrezTM 10 hydroalcoholic gels. Eur J Pharm Biopharm. 2002;54(3):329-335.
39. Lubrizol Advanced Materials Inc. Neutralizing Carbopol® and Pemulen™ polymers in aqueous and hydroalcoholic systems. Cleveland, OH: The Lubrizol Corporation; 2009. Dovepress
40. Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224(1-2):1-18.
41. Walters KA, Hadgraft J, editors. Pharmaceutical Skin Penetration Enhancement. New York, NY: Marcel Dekker; 1993.
42. Okuyama H, Ikeda Y, Kasai S, Imamori K, Takayama K, Nagai T. Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm. Int J Pharm. 1999; 186(2):141-148.
43. López A, Llinares F, Cortell C, Herráez M. Comparative enhancer effects of Span® 20 with Tween® 20 and Azone® on the in vitro percutaneous penetration of compounds with different lipophilicities. Int J Pharm. 2000;202(1-2):133-140.
44. Shin S-C, Cho C-W, Oh I-J. Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. Int J Pharm. 2001;222(2):199-203.
45. Abdullah GZ, Abdulkarim MF, Chitneni M, et al. Preparation and in vitro evaluation of mebeverine HCl colon-targeted drug delivery system. Pharm Dev Technol. April 30, 2010. [Epub ahead of print].
46. Liu R, editor. Water-insoluble Drug Formulation. New York, NY: CRC Press; 2000.
47. Hadgraft J, Valenta C. pH, pKa and dermal delivery. Int J Pharm. 2000; 200(2):243-247.
48. Hadgraft J, Plessis JD, Goosen C. The selection of non-steroidal antiinflammatory agents for dermal delivery. Int J Pharm. 2000; 207(1-2):31-37.
49. Hadgraft J, Walters KA, Wotton PK. Facilitated percutaneous absorption: a comparison and evaluation of two in vitro models. Int J Pharm. 1986;32(2-3):257-263.
50. Green PG, Hadgraft J. Facilitated transfer of cationic drugs across a lipoidal membrane by oleic acid and lauric acid. Int J Pharm. 1987; 37(3):251-255.
51. Veiga APC, Duarte IDG, Vila MNA, Motta PCGD, Tatsuo MAKF, Francischi JN. Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004;75(23):2807-2817.
52. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283(3): 1069-1076.